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We thank Dr Raja for his interest in our manuscript [1].
The strategy for management of blood glucose in the
perioperative period was performed in a standardised
fashion, according to our institutional standards, and is in
line with the recently published guidelines on the perio-
perative management of diabetes in cardiac and vascular
surgery [2,3]. In general, perioperative normoglycaemia was
aimed at, and a minimal disturbance of the patients’ habitual
blood glucose balance was anticipated. Hypoglycaemia was
avoided whenever possible, whereas hyperglycaemia was
immediately corrected to a level of 6—10 mmol l1. The
evening before the operation, oral antidiabetics were
stopped and only the standard dose of long-acting insulin
(the patient was used to) was applied subcutaneously. On the
day of operation, also any type of oral antidiabetics was
avoided and no baseline insulin was applied to the patient. By
contrast, the blood glucose level was measured in the early
morning and was corrected prior to the operation using
actrapid, if necessary. During the operation, the blood
glucose level was continuously monitored; if it was too high,
it was corrected using an actrapid perfusor (1—6 IE h1) and if
too low, glucose 5% was infused (200 ml h1). After the
operation, the therapy was changed to the habitual settings
as soon as possible.patients being from the early part of the study, whereas most
of OPCAB patients were from the later part of the study period
[6]. Therefore, a certain difference was visible with regard to
the choice of grafts, as the usage of arterial grafts or even total
arterial grafting constitutes nowadays the standard of care at
our institution for patients under the age of 70 years, whereas,
in earlier days, the usage of saphenous vein grafts was a
common approach to revascularise these patients.
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cardiac surgery; Congenital heart disease; SeizuresI have read with interest the article of Martin et al. and I
would like to make some comments [1]. The risks, benefits,
